University of Cambridge Laboratories select HALO AITM deep learning technology to advance metabolic disease research

Indica Labs / News  / University of Cambridge Laboratories select HALO AITM deep learning technology to advance metabolic disease research

University of Cambridge Laboratories select HALO AITM deep learning technology to advance metabolic disease research

Corrales, NM – October 5, 2017 – Indica Labs Inc headquartered in Corrales, New Mexico, is pleased to announce the selection of the newly developed deep learning classification tool, HALO AITM, by the University of Cambridge Metabolic Research Laboratories (MRL) in England.

HALO AI or ‘Artificial intelligence’ is a convolutional neural network platform resulting from years of effort by the Indica Labs’ research & development team, whose goal was to build a deep learning tool that could decipher and assess the complex patterns of histologically stained tissues, in a similar way to the brain of the pathologist. HALO AI was put to the test earlier this year in the Camelyon 17 challenge to determine TNM staging in 100 breast cancer patients where it scored highest amongst all commercial participants.
HALO AI will be used within the Metabolic Research Labs Imaging Core at the Welcome Trust-MRC, Institute of Metabolic Science. The decision of the MRL to acquire HALO AI came after an extensive evaluation through a series of proof-of-concept studies, including the evaluation of necrosis and inflammation in acute liver damage, measurement of placental zones during different stages of gestation, and detection of glomeruli in kidney tissue (as shown above).

“Image analysis is now moving towards machine learning and deep neural network algorithms and we would like to be at the forefront of these emerging developments,” said Gregory Strachan of the University of Cambridge. “We expect the Indica Labs’ HALO AI classifier to be an important new tool in our Translational Research Facility, opening up high-throughput analysis and more accurate tissue classification. Combined with HALO’s powerful analysis tools on whole tissue slide images, we should be able to deliver robust results much more quickly.”

Indica Labs CEO, Steven Hashagen, added, “Artificial intelligence is moving medical imaging into an exciting new era and digital pathology is no exception. We know that the earlier adopters like the University of Cambridge MRL will push out the boundaries with HALO AI to discover applications for this emerging technology that we never imagined. We are incredibly excited to see what advances come from this collaboration.”

Funding for purchase of HALO AI was provided by the Wellcome Trust Strategic Award [100574/Z/12/Z].

About the University of Cambridge Metabolic Research Laboratories (MRL)
The MRL brings together outstanding scientific and clinical researchers from 23 laboratories to form an international centre of excellence for research into metabolism and metabolic disease. MRL scientists collaborate to improve understanding, prevention and treatment of diabetes, obesity and other related endocrine and metabolic disorders, and to develop treatments for these conditions. The MRL is the base for the Medical Research Council (MRC) Metabolic Diseases Unit, which was awarded in 2013 as part of a strategic funding partnership between Wellcome and the MRC.

About Indica Labs
Indica Labs is a leading provider of software for quantitative evaluation of digital pathology images. Indica Labs’ HALO™ image analysis platform provides a unique combination of precision, performance, scalability, and usability which underpins a broad range of industry-leading, application-specific image analysis modules. Pharmaceutical and medical research organizations worldwide utilize HALO to support tissue-based research programs in immuno-oncology, oncology, neuroscience, metabolism, toxicological pathology, and more. For more information, please visit